DURECT (DRRX): רווח נקי למניה ב-12 החודשים האחרונים
DURECT Corporation focuses on epigenetics, utilizing the proprietary DUR-928 for liver cell restoration. This rolling annual EPS chart provided by GURU.Markets demonstrates profit dynamics, where the current level is approximately -0.47. The business model relies on outsourced manufacturing, and its independence from macroeconomic factors makes the asset a resilient defensive tool during recessionary periods.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_DRRX_-_DURECT-Corporation_-_Earnings-per-share-for-the-last-twelve-months "DRRX (DURECT) היסטוריית רווח נקי למניה (EPS TTM) מ-04.07.2022 עד 27.09.2025 | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור durect.com (DRRX)
The specifics of the biotechnology sector for DURECT Corporation (DRRX) entail high R&D expenses coupled with a deficit of operating income. This metric is calculated as the ratio of total annual net income to the number of shares outstanding. It measures the actual efficiency of capital allocation and the business's ability to generate value. The negative trend in the company's net income per share over 12 months confirms a stage of burning through reserves. Analysis of this chart allows for an assessment of the rate of capital depletion.
